JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (8): 1-5.doi: 10.6040/j.issn.1671-7554.0.2015.1336

    Next Articles

Effects of the overexpression of type 4 angiotensin receptor on the formation of atherosclerotic lesions

WEI Dandan, ZHANG Cheng   

  1. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2015-12-24 Online:2016-08-10 Published:2016-08-10

Abstract: Objective To explore the effects of type 4 angiotensin receptor(AT4R)on the formation of atherosclerotic lesions and to elaborate the possible mechanism. Methods A total of 60 apolipoprotein E-deficient mice fed with high-fat diet for 4 weeks were randomly divided into 3 groups: control group(receiving infusion of PBS), Ad-EGFP group(receiving infusion of adenoviral vectors with green fluorescence protein)and Ad-AT4R group(receiving infusion of adenoviral vectors with AT4R). High-fat diet lasted for another 4 weeks and then all mice were sacrificed to collect blood samples and whole aorta. The levels of blood glucose and blood lipid were measured. The aortic plaques were stained by HE and oil red O staining method to measure the percentage of positive atherosclerotic lesion area. Results There was no significant difference in blood glucose and serum lipid levels among the 3 groups. However, compared to the control group and the Ad-EGFP group, the Ad-AT4R group showed lower positive atherosclerotic lesion area stained by HE and oil red(P<0.05). Conclusion Overexpression of AT4R may inhibit the formation of atherosclerotic lesions independent of regulation of blood glucose and serum lipid. Thus AT4R may provide protection against atherosclerosis.

Key words: Type 4 angiotensin receptor, Atherosclerosis, Formation of atherosclerotic lesions

CLC Number: 

  • R543.1
[1] Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field[J]. Hypertension, 2001, 38(6): 1382-1387.
[2] Chai SY, Fernando R, Peck G, et al. The angiotensin Ⅳ/AT4 receptor[J]. Cell Mol Life Sci, 2004, 61(21): 2728-2737.
[3] Vanderheyden PM. From angiotensin Ⅳ binding site to AT4 receptor[J]. Mol Cell Endocrinol, 2009, 302(2): 159-166.
[4] Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin Ⅳ(AT(4))receptor is the enzyme insulin-regulated aminopeptidase[J]. J Biol Chem, 2001, 276(52): 48623-48626.
[5] Thomas WG, Mendelsohn FA. Angiotensin receptors: form and function and distribution[J]. Int J Biochem Cell Biol, 2003, 35(6): 774-779.
[6] Wright JW, Krebs LT, Stobb JW, et al. The angiotensin Ⅳ system: functional implications[J]. Front Neuroendocrinol, 1995, 16(1): 23-52.
[7] Patel JM, Martens JR, Li YD, et al. Angiotensin Ⅳ receptor-mediated activation of lung endothelial NOS is associatied with vasorelaxation[J]. 1998, 275(6 Pt 1): 1061-1068.
[8] Chen S, Patel JM, Block ER. Angiotensin Ⅳ-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release[J]. Am J Physiol Lung Cell Mol Physiol, 2000, 279(5): 849-856.
[9] Moeller I, Clune EF, Fennessy PA, et al. Up regulation of AT4 receptor levels in carotid arteries following balloon injury[J]. Regul Pept, 1999, 83(1): 25-30.
[10] Numaguchi Y, Ishii M, Kubota R, et al. Ablation of angiotensin Ⅳ receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis[J]. Arterioscler Thromb Vasc Biol, 2009, 29(12): 2102-2108.
[11] Yang H, Zeng XJ, Wang HX, et al. Angiotensin Ⅳ protects against angiotensin Ⅱ-induced cardiac injury via AT4 receptor[J]. Peptides, 2011, 32(10): 2108-2115.
[12] Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin Ⅳ treatment reverses endothelial dysfunction in ApoE-deficient mice[J]. Cardiovasc Res, 2008, 77(1): 178-187.
[13] Vinh A, Widdop RE, Chai SY, et al. Angiotensin Ⅳ-evoked vasoprotection is conserved in advanced atheroma[J]. Atherosclerosis, 2008, 200(1): 37-44.
[14] 蒲丽君, 黄颂敏. 血管紧张素Ⅳ/AT4受体系统研究进展[J]. 国际泌尿系统杂志, 2006, 26(2): 283-286.
[15] Faure S, Chapot R, Tallet D, et al. Cerebroprotective effect of angiotensin Ⅳ in experimental ischemic stroke in the rat mediated by AT(4)receptors[J]. J Physiol Pharmacol, 2006, 57(3): 329-342.
[16] Hall KL, Venkateswaran S, Hanesworth JM, et al. Characterization of a functional angiotensin Ⅳ receptor on coronary microvascular endothelial cells[J]. Regul Pept, 1995, 58(3): 107-115.
[17] Davis CJ, Kramar EA, De A, et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation[J]. Neuroscience, 2006, 137(4): 1369-1379.
[18] Lee J, Mustafa T, McDowall SG, et al. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase[J]. J Pharmacol Exp Ther, 2003, 305(1): 205-211.
[19] Lew RA, Mustafa T, Ye S, et al. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase(IRAP)[J]. J Neurochem, 2003, 86(2): 344-350.
[20] Handa RK, Harding JW, Simasko SM. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin Ⅳ and divalinal angiotensin Ⅳ as receptor ligands[J]. J Pharmacol Exp Ther, 1999, 291(3): 1242-1249.
[1] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24-31.
[2] YIN Ni, YANG Guanlin, JIANG Junwen, WANG Chuntian, WANG Fengyao, JIA Lianqun, GAO Xiaoyu, PAN Jiaxiang, LI Qin, LI Jia, FENG Yuanjie, GAO Yuzhu, ZHOU He, ZHANG Zhe. A reliable system to assess atherosclerosis model of Bama minipigs [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 1-5.
[3] WANG Dan, QI Hengtao, SUN Shuzhen. Changes of carotid artery structure and function in children with primary nephrotic syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 88-91.
[4] SUN Pengfei, MENG Xiao, ZHANG Kai, LI Li. The effect of resistin-like molecule β on the vulnerability of atherosclerotic plaques in ApoE-/- mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 1-4.
[5] WANG Xiaofei, WANG Chengwei, WANG Zhigang, DING Xuan, WANG Minqing. Application of enterprise stent in atherosclerotic vertebral-basilar arterial stenosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 44-48.
[6] YU Xin, LIU Xiaojing, LIU Xiangqun. The inhibitory effect of baicalin on endothelial cell apoptosis induced by ox-LDL [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 5-9.
[7] TAN Bei, GUAN Yuqing, SUN Hui, HU Keqing, SU Guohai, WEI Min. Effects of atorvastatin with intravascular ultrasound on atherosclerotic plaques in rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 10-14.
[8] DUAN Ruisheng. Immune-regulation of statins in atherosclerosis and opinions on its clinical applications [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 1-4.
[9] YU Lei, LI Zhen. Expression of interleukin-33 and its function in the serum of patients with cerebrovascular disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 75-79.
[10] XU Zhongyang, WANG Liqi, XU Zhenxing, ZHAO Qian, ZHU Shiming. Correlations among RhoA/ROCK signaling pathway, blood pressure variability and carotid artery intima-media thickness in essential hypertensive patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 48-51.
[11] RONG Chunli, YAO Wenjing, YANG Qian, LI Ruyi, CAO Dongping, LIU Meixia, PENG Yingxin. Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 46-49.
[12] JIN Chengwei, LI Kui, ZHAO Jing, YUE Xin, SHANG Yuanyuan, HAN Lu, ZHANG Yun, ZHANG Wei, MA Xiao, ZHONG Ming. Relationship between the mRNA expression of adipose triglyceride lipase in peripheral blood mononuclear cells and metabolic syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 39-42.
[13] LI Yueyan1, GUAN Yuqing2, MIAO Wei2, HU Keqing2, HU Hongyan3, LI Ying2, WANG Xiaoqi2, SU Guohai2. Effect of atorvastatin on TLR4 expression and downstream signaling in atherosclerotic rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 1-6.
[14] HAO Fengcheng1,2, SU Zhonghua1,3. Protective effect of autophagy on the inflammation induced by ox-LDL [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 30-34.
[15] HAO Qingqing1,2,3, ZHANG Yonghuan1,2,3, YU Qingtao1,2, ZHU Li1,2, CHEN Xu1,2, LI Shuying1,2, WANG Laicheng1,2, ZHANG Yuehui1,4, LI Ruifeng3,. Effects of ACE2 gene transfection on adhesion molecules in atherosclerotic plaque of ApoE-/- mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 1-6.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!